Repurposed drugs for COVID-19: threshold and proof requirements for trials

Clin Microbiol Infect. 2021 Dec;27(12):1716-1717. doi: 10.1016/j.cmi.2021.08.024. Epub 2021 Sep 8.

Authors

Mical Paul¹, Andre C Kalil²

Affiliations

¹ Division of Infectious Diseases, Rambam Health Care Campus and The Ruth and Bruce Rappaport, Technion-Israel Institute of Technology, Israel. Electronic address: paulm@technion.ac.il.
² Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antiviral Agents / therapeutic use
COVID-19*
Drug Repositioning
Humans
Pharmaceutical Preparations*
SARS-CoV-2

Substances

Antiviral Agents
Pharmaceutical Preparations